| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended July 2, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/19/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and the several underwriters listed on Schedule I to the Pricing Agreement",
"Pricing Agreement, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and the several underwriters listed on Schedule I to the Pricing Agreement",
"Indenture, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and The Bank of New York Mellon, as trustee",
"First Supplemental Indenture, among Pfizer Investment Enterprises Pte. Ltd., Pfizer Inc. and The Bank of New York Mellon, as trustee",
"Opinion of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company",
"Opinion of Drew & Napier LLC" |
|
| 05/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
SC 13D/A
| PFIZER INC reports a 32% stake in HALEON PLC |
| 05/15/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/15/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 05/15/2023 |
8-K
| Other Events Interactive Data |
| 05/02/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/04/2023 |
PX14A6G
| Form PX14A6G - Notice of exempt solicitation submitted by non-management: |
| 03/27/2023 |
SC 13D/A
| PFIZER INC reports a 17.3% stake in LONGBOARD PHARMACEUTICALS, INC. |
| 03/23/2023 |
SC 13G/A
| PFIZER INC reports a 19% stake in Pyxis Oncology, Inc. |
| 03/22/2023 |
PX14A6G
| Form PX14A6G - Notice of exempt solicitation submitted by non-management: |
| 03/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/16/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
8-K
| Acquisition/merger/asset purchase announced |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/07/2023 |
SC 13G/A
| STATE STREET CORP reports a 5.1% stake in AMENDED FILING PFIZER INC |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13D/A
| PFIZER INC reports a 32% stake in HALEON PLC |
| 01/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 12/29/2022 |
SC 13G
| PFIZER INC reports a 12% stake in ORIC PHARMACEUTICALS, INC. |
| 12/13/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended October 2, 2022 |
| 11/01/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended July 3, 2022 |
| 07/28/2022 |
8-K
| Quarterly results |
|